Ocugen Maintains ‘Buy’ Rating on Strong OCU410ST Regulatory Progress

Biotech company Ocugen, Inc. (OCGN) continues to earn a “Buy” rating from analysts following favorable regulatory developments surrounding its gene therapy candidate OCU410ST, designed to treat Stargardt disease, a rare inherited retinal disorder with no current cure. The positive outlook stems from significant regulatory alignment between the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), which now allows Ocugen to use a single U.S. Phase 2/3 pivotal trial (GARDian3) to support both a Biologics License Application (BLA) in the United States and a Marketing Authorization Application (MAA) in Europe. Interim data from the GARDian3 trial is expected by mid‑2026, and if the results are positive, Ocugen could pursue a BLA submission in 2027. However, while the regulatory trajectory is encouraging, the company’s financial runway extends only into the second quarter of 2026, and cash burn remains a risk—though warrant exercises might add roughly $30 million in funding. Overall, these developments reinforce investor confidence in Ocugen’s gene therapy pipeline and its potential to bring the first treatment for Stargardt disease to market. #Ocugen #OCU410ST #GeneTherapy #StargardtDisease #SlimScan #GrowthStocks #CANSLIM